跳至主要内容
临床试验/ACTRN12624000869572
ACTRN12624000869572尚未招募1 期

Pilot study of the feasibility and acceptability of administration of psilocybin in healthy volunteers within a marae setting

Matai Medical Research Institute0 个研究点目标入组 12 人开始时间: 2024年7月16日最近更新:

试验速览

阶段
1 期
状态
尚未招募
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 65 Years(—)
性别
All

入选标准

  • 1.Provision of signed and dated informed consent form.
  • 2.Stated willingness to comply with all study procedures and availability for the duration of the study.
  • 3.Maori, of any gender identity aged, 18-65 years.
  • 4.For heterosexually active persons of child-bearing potential: agree to use an effective or highly effective contraception for at least one month prior to screening and agreement to use such a method for one month after follow-up is completed
  • 5.For heterosexually active males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner. These participants must also agree not to donate sperm until at least 3 months after receiving the study drug

排除标准

  • 1.Current or past history of schizophrenia or other psychotic disorders, or bipolar I or II disorder. Also excluded will be individuals with a known first-degree relative with these disorders.
  • 2.Risk of suicide as determined by The Columbia-Suicide Severity Rating Scale (C-SSRS).
  • 3.Current diagnosis of depression, any anxiety disorder, post-traumatic stress disorder (PTSD), or eating disorder. Previous diagnoses are acceptable provided remission has been stable for at least three years.
  • 4.Substance dependence in the previous 6 months. Use as assessed by clinical interview with a New Zealand modified version of the NIDA (National Institute of Drug Abuse) Modified Alcohol, Smoking and Substance. Involvement Screening Test (NM-ASSIST).
  • 5.Problematic use of alcohol defined as a score on the Alcohol Use Disorders Identification Test (AUDIT) of 16 or greater.
  • 6.Body Mass Index (BMI) <18 and > 35.
  • 7.Planned or current pregnancy or lactation.
  • 8.Cardiovascular conditions including abnormal heart rate or blood pressure to be checked at screening. A threshold of exceeding 160 mmHg (systolic) and 90 mmHg (diastolic) averaged across three assessments taken on the screening day will be used. Participants with well-managed hypertension would not be excluded.
  • 9.Significant renal or hepatic impairment.
  • 10.Abnormal 12-lead electrocardiogram (ECG) as judged by a study physician.
  • 11.Any unstable medical or neurological condition.
  • 12.Regular use of any medication/supplements deemed to be contraindicating as judged by a study physician
  • 13.Treatment with another investigational drug or other intervention within 2 months.
  • 14.Use of serotonergic psychedelic drugs in the last year.
  • 15.Any other condition judged by the treating clinician as likely to impact on the ability of the participant to complete the trial.

研究者

发起方
Matai Medical Research Institute

相似试验